The cardiotoxicity of doxorubicin (DOX) may manifest at the beginning/during treatment or
years after, compromising patients' quality of life. We intended to study the cardiac pathways …

Doxorubicin (DOX) and mitoxantrone (MTX) are classical chemotherapeutic agents used in
cancer that induce similar clinical cardiotoxic effects, although it is not clear if they share …

Doxorubicin (Dox) is a highly effective anticancer drug but cause acute ventricular
dysfunction, and also induce late-onset cardiomyopathy and heart failure. Despite extensive …

Doxorubicin (DOX) is an effective anthracycline used in chemotherapeutic regimens for a
variety of haematological and solid tumors. However, its utility remains limited by its well …

Doxorubicin (DOX) is a potent chemotherapeutic agent used against several cancer types.
However, due to its cardiotoxic adverse effects, the use of this drug may be also life …

Doxorubicin (DOX) is a highly effective chemotherapeutic agent used in the treatment of
various cancer types. Nevertheless, it is well known that DOX promotes the development of …

Doxorubicin (DOX) is a highly effective chemotherapeutic agent whose clinical use is
hindered by the onset of cardiotoxic effects, resulting in reduced ejection fraction within the …

Doxorubicin (DOX) is an anthracycline antineoplastic agent that has limited clinical utility
due to its dose-dependent cardiotoxicity. Although the exact mechanism remains unknown …

Doxorubicin (Dox) is an effective chemotherapeutic agent, however, its use is limited by
cardiotoxicity. The mechanisms causing cardiotoxicity have not been clearly elucidated, but …

Doxorubicin (Dox), an anthracycline antibiotic, is an anticancer drug that inhibits DNA
replication and cellular metabolic processes in cancer cells with high proliferative potential …